Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Investigator
- Diana Barb
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All
Diana Barb, MD
Endocrinologist (Diabetes & Hormones Specialist)
Rated
4.7
out of 5 stars
About me
Dr. Diana Barb received her medical degree from the University of Medicine and Pharmacy in Targu Mures Romania. She did a two year research fellowship, focusing on obesity, adiponectin and cancer at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts, followed by an Internship, Internal Medicine Residency and Endocrinology Fellowship at Emory University in Atlanta, Georgia. Subsequently, she joined the University of Florida as a Clinical Associate Professor in the Division of Endocrinology, Diabetes & Metabolism.
Accepted insurances
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesMy locations
Active clinical trials
My research
Top areas of exploration
- Diabetes Mellitus, Type 2 , 20 publications
- Non-alcoholic Fatty Liver Disease , 19 publications
- Insulin Resistance , 12 publications
- Liver , 12 publications
Research activity
My areas of focus
Stories and news
UF Health researchers study association between type 2 diabetes and fatty liver disease
November 20, 2018
Too often, the wisps of smoke go unnoticed long before the raging conflagration erupts. The story of nonalcoholic fatty liver disease, or NAFLD, is often…
College of Medicine, Diabetes Institute, +2 more
